RB1 and neoplasm: Other detected homozygous somatic variants included TP53 (c.607G > T p.Val203Leu, VAF 85%, class 3–4) and RB1 (c.2239G > T p.Glu747 *, VAF 85%, class 4–5) During the molecular tumor board meeting both the TSC1 and NF1 variants were considered a potential candidate target rendering sensitivity to mTOR inhibition (Figure 3), even though the initial treatment with everolimus had not, evidently, been successful in this patient.